Fintel reports that on December 4, 2025, Canaccord Genuity maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) ...
Morgan Stanley has downgraded Regeneron Pharmaceuticals ( REGN) to equal-weight from overweight saying that the stock is fairly valued. The bank maintained its price target of $767 (~3% upside based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback